November 17, 2016 - By Vivian Park · 0 Comments
Medicinova Inc (NASDAQ:MNOV) institutional sentiment decreased to 1.83 in 2016 Q2. Its down -1.80, from 3.63 in 2016Q1. The ratio has dropped, as 33 investment managers opened new and increased equity positions, while 18 cut down and sold their positions in Medicinova Inc. The investment managers in our partner’s database now hold: 7.44 million shares, down from 14.69 million shares in 2016Q1. Also, the number of investment managers holding Medicinova Inc in their top 10 equity positions was flat from 1 to 1 for the same number . Sold All: 12 Reduced: 6 Increased: 14 New Position: 19.
MediciNova, Inc. is a biopharmaceutical company. The company has a market cap of $265.56 million. The Firm is focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It currently has negative earnings. It is focused on its development activities on MN-166 for neurological disorders and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).
About 35,050 shares traded hands. MediciNova, Inc. (NASDAQ:MNOV) has declined 15.14% since April 15, 2016 and is downtrending. It has underperformed by 19.77% the S&P500.
According to Zacks Investment Research, “MEDICINOVA, INC. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova’s pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova will seek to monetize its other product candidates at key value inflection points.”
Essex Woodlands Health Ventures Inc. holds 2.23% of its portfolio in MediciNova, Inc. for 1.17 million shares. Evanson Asset Management Llc owns 15,000 shares or 0.03% of their US portfolio. Moreover, Bridgeway Capital Management Inc has 0.01% invested in the company for 94,082 shares. The Texas-based Highland Capital Management Lp has invested 0.01% in the stock. Oxford Asset Management, a United Kingdom-based fund reported 44,734 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 2 insider purchases, and 1 insider sale for $116,292 net activity.
More recent MediciNova, Inc. (NASDAQ:MNOV) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on April 14, 2011. Also Reuters.com published the news titled: “BRIEF-Medicinova Inc – expected basic, diluted loss per share for year end…” on October 26, 2016. Quotes.Wsj.com‘s news article titled: “MediciNova Inc. MNOV (US: Nasdaq)” with publication date: February 11, 2011 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Vivian Park